Drug Trial Radar · NCT07012395
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
645
Planned (sponsor's estimate)
Start
May 27, 2025
Primary completion
Jun 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- Spyre Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.
Conditions
- Ulcerative Colitis
- Inflammatory Bowel Diseases
- Colitis
- Colitis, Ulcerative
Interventions
SPY001Drug
Experimental
SPY002Drug
Experimental
SPY003Drug
Experimental
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Change in Robarts Histopathology Index (RHI)Time frame: Week 12
- Part B: Percentage of participants with clinical remissionTime frame: Week 12
Locations
279 sites in 36 countries. Site status is shown where the registry gives one.
Site 024
Canoga Park, California · Recruiting
Site 023
La Jolla, California · Recruiting
Site 012
Lancaster, California · Recruiting
Site 033
Colorado Springs, Colorado · Recruiting
Site 007
Kissimmee, Florida · Recruiting
029
Miami, Florida · Recruiting
Site 038
Chicago, Illinois · Recruiting
Site 006
Kansas City, Kansas · Recruiting
Site 030
Louisville, Kentucky · Recruiting
Site 035
Marrero, Louisiana · Recruiting
Site 011
Glen Burnie, Maryland · Recruiting
Site 003
Boston, Massachusetts · Recruiting
Site 028
Rochester, Minnesota · Recruiting
Site 039
St Louis, Missouri · Recruiting
Site 037
New York, New York · Recruiting
040
Chapel Hill, North Carolina · Recruiting
Site 041
Durham, North Carolina · Recruiting
Site 016
Winston-Salem, North Carolina · Recruiting
Site 025
Providence, Rhode Island · Recruiting
Site 017
Kingsport, Tennessee · Recruiting
Site 013
Cedar Park, Texas · Recruiting
Site 005
Garland, Texas · Recruiting
Site 002
San Antonio, Texas · Recruiting
Site 008
Southlake, Texas · Recruiting
Site 009
Webster, Texas · Recruiting
Site 004
Seattle, Washington · Recruiting
Site 019
Tacoma, Washington · Recruiting
Site 105
La Plata, Buenos Aires, Argentina · Recruiting
Site 102
Lujan de Cuyo, Mendoza Province, Argentina · Recruiting
Site 103
Rosario, Sant Fe, Argentina · Recruiting
Site 104
San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting
Site 208
Concord, Australia · Recruiting
Site 202
Heidelberg, Australia · Recruiting
Site 204
Liverpool, Australia · Recruiting
Site 203
Melbourne, Australia · Recruiting
Site 206
South Brisbane, Australia · Recruiting
Site 207
Woolloongabba, Australia · Recruiting
Site 201
Murdoch, Western Australia, Australia · Recruiting
Site 463
Linz, Austria · Recruiting
Site 461
Salzburg, Austria · Recruiting
Showing 40 of 279 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.